Resources

LifeArc and the Gates Foundation are funding seven ground-breaking new projects launched to lower the cost of monoclonal antibody production to make them more accessible globally.

From scaling up advanced therapy manufacturing to harnessing the power of digital and automation, Ed Samuel, the new COO of the CGT Catapult, discusses how collaboration and innovation will shape the next phase of the UK’s cell and gene therapy ecosystem.

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

R&D-focused collaboration aims to streamline the connectivity between Cytiva’s equipment and overarching site control systems, such as zenon POL (Process Orchestration Layer), answering significant demand from customers for efficient integration solutions in the biopharmaceutical and biotechnology industries.

The BIA moves into a new era this week, amidst news from the US on tariffs for UK pharma, UK political party conferences underway and a change in leadership at GSK. It’s full steam ahead for BIA towards a busy Autumn, ensuring that the life science sector stays at the top of the government’s priority list and that our members are represented and connected.

This is my final CEO update in Newscast after 13 years at the BIA. I take up my new role as Executive Chair of the Office for Life Sciences next Monday. Before I do, I want to thank you - my loyal readers - for engaging with my musings over the years, and for your feedback that has improved this blog and my thinking.

Abzena has announced the expansion of our AbZelectPRO™ cell line development (CLD) platform with the launch of two next-gen Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Asymchem, has announced a significant expansion of its flow chemistry capabilities at its Sandwich, UK facility.

Cotton Mouton Diagnostics (CMD), a cutting-edge UK-based diagnostics technology company, has received a half-a-million-pound investment from CPI Enterprises as part of the Innovate UK Catapult Investment Pilot.

 In this blog, Abby Clark builds on a round table the BIA hosted with Chi Onwurah MP and Newcastle life science companies to explore the landscape and the drivers which make the sector strong, yet undervalued. 

In this blog, James Buckley-Walker, Partner, 3PM, shares his vision of a smarter, more human-focused approach to lab design and operation.

Rinri Therapeutics is focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, providing new therapeutic options for the treatment of this major global unmet medical need.

Aravax announced the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company’s Oxford, UK site.

A Scottish clinical development company is redefining early stage development, taking years off the time it takes for new life improving treatments to become available to patients. BDD Pharma Ltd – based at BioCity Glasgow, one of two Pioneer Group sites in Scotland – has also developed its own, in-house technologies. One of them - OralogiK™ - is a unique patented drug delivery tablet system that enables drugs to be released inside the body at the optimum time, hours after taking the tablets.

Moderna Innovation and Technology Centre (MITC) at Harwell Science and Innovation Campus has been granted a Manufacturer’s/Importer’s Authorisation (MIA) by the MHRA.

Proprietary formulation technology is being applied to potentially enhance properties of nimacimab.